News | Pacemakers | November 10, 2017

Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization

Study results suggest new option for patients that cannot afford a pacemaker

Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization

November 10, 2017 — Mexican doctors have safely reused donated pacemakers after sterilization, according to a study presented at the 30th Mexican Congress of Cardiology, Nov. 2-5, 2017, in Guadalajara, Mexico. The findings create the possibility for patients to receive a pacemaker who otherwise could not afford one.

“There is no report of the number of pacemaker implants per year in Mexico, but we implant close to 150 new pacemakers per year in our hospital,” said first author Carlos Gutiérrez, M.D., a cardiologist at the General Hospital of Mexico "Dr. Eduardo Liceaga" in Mexico City.

“According to government reports, more than half of the population in Mexico does not have access to social security or private insurance that covers a pacemaker implant, and 44 percent live in poverty,” he continued.1 “This suggests that many Mexicans cannot afford a pacemaker. Previous studies have shown the safety of reusing pacemakers after sterilization.”

The current study included 33 patients with a pacing indication who could not afford a new pacemaker or a battery change. Patients received a reused device at the General Hospital of Mexico between 2011 and 2017. Devices had been donated by relatives of deceased patients and had a minimum of six years of battery life.

After confirming that the pacemakers were functioning correctly, they were washed with enzymatic soap and sterilized in an autoclave for 38 minutes. Pacemaker function was rechecked after sterilization.

Patients were 72 years old on average (the age range was 20 to 106) and 52 percent were female. The indications for a pacemaker were sinus node dysfunction in ten patients (30 percent) and advanced atrioventricular block in 23 patients (70 percent).

Of the 33 patients, 25 received a reused pacemaker. Eight patients already had a pacemaker and received a reused generator (battery). During the implant procedure there was one hematoma which resolved without further complications. There were no complications during the six month follow-up period.

Gutiérrez said: “This was a small study but it shows that with a thorough and standardised sterilization process, explanted pacemakers with a battery life of more than six years can be reused safely. This provides an effective option for patients who cannot afford a new device or a replacement battery.”

“This practice could be implemented in many other centers that have equipment to sterilize and reprogram pacemakers,” continued Gutiérrez. “We also need to promote the donation of pacemakers with little use from deceased patients.”

Erick Alexanderson, M.D., president of the Mexican Society of Cardiology, said: “This study has encouraging results which open up the possibility of pacemaker treatment for many more Mexicans who need it.”

For more information: www.escardio.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now